Li, X., Wang, S., Wei, Y., Xie, C., Chen, Y., Wu, F., Zhou, Q., Song, X., Xu, X., Xu, D., Xu, L., Lin, S., Yuan, F. (2026). AR-targeted therapies sensitize prostate cancer to cuproptosis by transcriptionally activating
                    <i>FDX1</i>. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2534978123